Sean Michael Smith - Net Worth and Insider Trading
Sean Michael Smith Net Worth
The estimated net worth of Sean Michael Smith is at least $3,776 dollars as of 2024-11-05. Sean Michael Smith is the Interim CFO, Prin Acct Off of Neoleukin Therapeutics Inc and owns about 1,082 shares of Neoleukin Therapeutics Inc (NLTX) stock worth over $3,776. Details can be seen in Sean Michael Smith's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Sean Michael Smith has not made any transactions after 2023-08-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Sean Michael Smith
Sean Michael Smith Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Sean Michael Smith owns 1 companies in total, including Neoleukin Therapeutics Inc (NLTX) .
Click here to see the complete history of Sean Michael Smith’s form 4 insider trades.
Insider Ownership Summary of Sean Michael Smith
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NLTX | Neoleukin Therapeutics Inc | 2023-08-11 | Principal Accounting Officer |
Sean Michael Smith Latest Holdings Summary
Sean Michael Smith currently owns a total of 1 stock. Sean Michael Smith owns 1,082 shares of Neoleukin Therapeutics Inc (NLTX) as of August 11, 2023, with a value of $3,776.
Latest Holdings of Sean Michael Smith
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NLTX | Neoleukin Therapeutics Inc | 2023-08-11 | 1,082 | 3.49 | 3,776 |
Holding Weightings of Sean Michael Smith
Sean Michael Smith Form 4 Trading Tracker
According to the SEC Form 4 filings, Sean Michael Smith has made a total of 3 transactions in Neoleukin Therapeutics Inc (NLTX) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Neoleukin Therapeutics Inc is the sale of 66 shares on August 11, 2023, which brought Sean Michael Smith around $820.
Insider Trading History of Sean Michael Smith
- 1
Sean Michael Smith Trading Performance
Sean Michael Smith Ownership Network
Ownership Network List of Sean Michael Smith
Ownership Network Relation of Sean Michael Smith
Sean Michael Smith Owned Company Details
What does Neoleukin Therapeutics Inc do?
Who are the key executives at Neoleukin Therapeutics Inc?
Sean Michael Smith is the Principal Accounting Officer of Neoleukin Therapeutics Inc. Other key executives at Neoleukin Therapeutics Inc include 10 percent owner Baker Bros. Advisors Lp , Chief Medical Officer Priti Patel , and General Counsel & SVP Legal Donna Cochener .
Neoleukin Therapeutics Inc (NLTX) Insider Trades Summary
Over the past 18 months, Sean Michael Smith made 1 insider transaction in Neoleukin Therapeutics Inc (NLTX) with a net sale of 1,323. Other recent insider transactions involving Neoleukin Therapeutics Inc (NLTX) include a net purchase of 2,285,342 shares made by Baker Bros. Advisors Lp ,
In summary, during the past 3 months, insiders sold 0 shares of Neoleukin Therapeutics Inc (NLTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 66 shares of Neoleukin Therapeutics Inc (NLTX) were sold and 114,267 shares were bought by its insiders, resulting in a net purchase of 114,201 shares.
Neoleukin Therapeutics Inc (NLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Neoleukin Therapeutics Inc Insider Transactions
Sean Michael Smith Mailing Address
Above is the net worth, insider trading, and ownership report for Sean Michael Smith. You might contact Sean Michael Smith via mailing address: C/o Neoleukin Therapeutics, Inc., 188 E. Blaine Street, Suite 450, Seattle Wa 98102.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
